drugset / Trial / NCT04175431
Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well prostate specific membrane antigen (PSMA) or fluciclovine positron emission tomography (PET)/computed tomography (CT) site-directed therapy works for treating patients with prostate cancer. PSMA or fluciclovine PET/CT may detect prostate cancer early and may help to show whether patients benefit from site directed treatment to PET detected abnormalities.
Timeline
- Start
- 2020-09-30
- Primary completion
- 2032-07-01
- Completion
- 2037-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |